Cargando…
Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction
BACKGROUND: Inhibiting both type 1 and 2 sodium–glucose linked cotransporter (SGLT1/2) offers the potential to not only increase glucosuria beyond that seen with selective SGLT2 inhibition alone but to reduce glucose absorption from the gut and to thereby also stimulate glucagon-like peptide 1 secre...
Autores principales: | Connelly, Kim A., Zhang, Yanling, Desjardins, Jean-François, Thai, Kerri, Gilbert, Richard E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035399/ https://www.ncbi.nlm.nih.gov/pubmed/29981571 http://dx.doi.org/10.1186/s12933-018-0741-9 |
Ejemplares similares
-
Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
por: Gilbert, Richard E., et al.
Publicado: (2019) -
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
por: Zhang, Yanling, et al.
Publicado: (2016) -
Impact of sodium glucose linked cotransporter‐2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus
por: Hare, Gregory M. T., et al.
Publicado: (2021) -
Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
por: Sayour, Alex Ali, et al.
Publicado: (2020) -
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020)